Inflammation as target in cancer therapy

Area of Science:

• Immunology
• Oncology
• Cancer Research

Background:

• Innate immune cells infiltrate tumors, paradoxically promoting cancer proliferation and metastasis.
• Tumor-associated macrophages (TAMs) are key drivers of chronic inflammation within the tumor microenvironment.
• This inflammation creates an immunosuppressive environment, fostering disease development.

Purpose of the Study:

• To investigate the role of innate immunity in cancer progression.
• To evaluate therapeutic strategies targeting inflammatory cells and their products in cancer.
• To assess the clinical efficacy and safety of targeting TAMs and inflammation in solid malignancies.

Main Methods:

• Review of pre-clinical tumor models demonstrating success with anti-inflammatory strategies.
• Analysis of early-phase clinical trials involving cytokine/chemokine inhibitors and TAM-targeting agents.
• Evaluation of patient responses and toxicity profiles in ongoing clinical studies.

Main Results:

• Therapeutic strategies targeting inflammatory cells and products showed success in pre-clinical models.
• Early clinical trials in solid tumors yielded partial responses and disease stabilization.
• Treatments were generally well-tolerated with no significant toxicity observed.

Conclusions:

• Targeting cancer-promoting inflammation and TAMs represents a promising therapeutic avenue.
• Combination treatments reducing inflammation may enhance anti-tumor efficacy.
• Encouraging early clinical results warrant further investigation into these novel strategies.